Biogen cost cuts drive profit beat, Alzheimer's drug sales jump
Reuters
Published Apr 24, 2024 06:48AM ET
Updated Apr 24, 2024 08:57AM ET
By Manas Mishra and Sriparna Roy
(Reuters) -Biogen beat market estimates for first-quarter profit on Wednesday as a series of cost-cutting measures helped offset the impact of fierce competition for its older drugs, sending its shares up nearly 7% before the bell.
The company also said sales of Alzheimer's drug Leqembi, recorded by Japanese partner Eisai, nearly tripled quarter-over-quarter to about $19 million. That was below lofty Wall Street expectations of $30 million, according to consensus estimates compiled by Jefferies.
Bottlenecks due to Leqembi's requirements such as additional diagnostic tests, twice-monthly infusions and regular brain scans have contributed to a slower adoption of the drug than markets were expecting.
The launch has led to profound changes in how doctors treat Alzheimer's patients, and challenges include the "amount of effort it takes to actually be able to initiate even the first patient", CEO Christopher Viehbacher said in an interview.
"I do think we're now on a positive track. I think we're seeing momentum," he said, but does not expect the launch to be linear.
The number of patients on Leqembi have increased nearly 2.5 times from roughly 2,000 patients at the end of 2023, Biogen (NASDAQ:BIIB) said. Eisai had previously aimed to treat 10,000 patients by March but indicated it would not meet the target in February.
While encouraging, the growth in patients needs to accelerate from here, Jefferies analyst Michael Yee said.
Leqembi is among the newer drugs that Biogen is hoping will drive growth for the next few years, as its multiple sclerosis therapies and spinal muscular atrophy treatment grapple with increased competition.
Sales of Biogen's once-blockbuster multiple sclerosis drug Tecfidera came in at $254.3 million, above estimates of $236.84 million, but spinal muscular atrophy drug Spinraza missed estimates.
Skyclarys, the drug Biogen gained through its $6.5 billion Reata acquisition, brought in sales of $78 million, above estimates of $72.3 million.
Biogen's adjusted profit per share of $3.67 beat analysts' estimates of $3.45, according to LSEG.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.